MARKET

ADRO

ADRO

Aduro Biotech
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.100
-0.030
-2.65%
After Hours: 1.100 0 0.00% 16:00 11/15 EST
OPEN
1.150
PREV CLOSE
1.130
HIGH
1.180
LOW
1.100
VOLUME
625.85K
TURNOVER
--
52 WEEK HIGH
4.590
52 WEEK LOW
0.9011
MARKET CAP
88.57M
P/E (TTM)
-0.9833
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of ADRO and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 6 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

ADRO News

  • Aduro Biotech Announces Presentation of Results from First-in-Human Phase 1 Study of Anti-CD27 Agonist as Monotherapy and in Combination with Pembrolizumab in Patients with Advanced Solid Tumors at the Society for Immunotherapy of Cancer 34th Annual Meeting
  • GlobeNewswire.11/08 21:05
  • Aduro (ADRO) Q3 Loss Wider Than Expected, Revenues Rise Y/Y
  • Zacks.11/08 17:20
  • Aduro Biotech EPS misses by $0.03, beats on revenue
  • seekingalpha.11/08 03:08
  • Aduro Biotech (ADRO) Reports Q3 Loss, Tops Revenue Estimates
  • Zacks.11/08 00:35

More

Industry

Biotechnology & Medical Research
+1.49%
Pharmaceuticals & Medical Research
+1.29%

Hot Stocks

Name
Price
%Change

About ADRO

Aduro Biotech, Inc. is an immunotherapy company, which focuses on the discovery, development and commercialization of therapies that manage the treatment of various diseases, including cancer. The Company's product candidates from its Live, Attenuated, Double-Deleted (LADD) Listeria monocytogenes, Stimulator of Interferon Genes Pathway Activator, and B-select monoclonal antibody platforms are designed to stimulate and/or regulate innate and adaptive immune responses, either as single agents or in combination with conventional therapies, as well as other immunotherapies. Its LADD technology platform is being developed as a treatment for multiple indications, including mesothelioma, ovarian, gastric, lung and prostate cancers. Its LADD product candidate is CRS-207, which is being developed as a treatment for multiple indications, including mesothelioma, ovarian and gastric cancers. ADU-214 and ADU-741 are product candidates in development for lung and prostate cancers, respectively.
More

Webull offers Aduro BioTech Inc (ADRO) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.